



Overview

MetaStat is a pre-commercial diagnostic company focused on the development and commercialization of novel Laboratory Developed Tests (LDTs) to provide physicians and patients actionable information regarding the risk of distant systemic metastasis. We believe cancer treatment strategies can be personalized and outcomes improved through new diagnostic tools that more accurately identify the aggressiveness and metastatic potential of primary tumors.

Systemic metastasis, cancer that spreads from a primary tumor to other areas of the body, is responsible for approximately 90% of all solid tumor cancer-related deaths. However, based on management estimates only 30-35% of breast cancer and 15% of prostate cancer tumors are biologically capable of metastatic spread, yet the majority of these patients are treated with aggressive therapies. We are developing two epigenetic-based diagnostic assays, called **MetaSite Breast™** and **MenaCalc™**, which we intend to offer as a LDT service available through our clinical reference laboratory based in Boston, MA. We anticipate receiving CLIA certification in 2015 and to begin commercializing our breast cancer diagnostic tests in 2016.

Our technology platform and corresponding products are the result of over 15 years of collaboration involving four scientific/academic institutions. We believe we are unique and differentiated in the marketplace. Our discoveries are based on direct microscopic visualization of living, functioning tumors in vivo, which enabled us to specifically isolate and thus characterize the behavior, genetics and mechanics of these highly metastatic cells.

Management Team

Douglas A. Hamilton, B.Sc., MBA
President and Chief Executive Officer

Michael J. Donovan, PhD, MD
Chief Medical Officer

Daniel H. Schneiderman
Vice President, Finance and Secretary

Heiner Dreismann, Ph.D.
Head of Diagnostics

Recent News

Monday, July 16, 2018 - 04:05 PM

[MetaStat Voluntarily Withdraws Listing on the OTCQB and Files Form 15 to Suspend its Reporting Obligations](#)

Thursday, June 21, 2018 - 07:30 AM

[MetaStat Presents Positive Data Showing Inhibition of the MENA-pathway Reduces Cancer Cell Dissemination and Paclitaxel Resistance in Aggressive Cancer](#)

DISCLAIMER

Except for the historical information contained herein, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on Form 10-K and its quarterly reports on Form 10-Q. The Company does not undertake any obligation to update forward-looking statements. All trademarks and brand names are the property of their respective companies.

Contact Information

MetaStat, Inc.
27 Drydock Ave.
2nd Floor
Boston, MA 02210

OTCPink: MTST



Share Price	\$0.05
Volume	0
Shares Outstanding	5,877,383
Market Cap	\$293.87k
52 Week High	\$1.00
52 Week Low	\$0.05

as of 04/30/2019